Rinat Yerushalmi

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi Ki67 in breast cancer: prognostic and predictive potential
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Lancet Oncol 11:174-83. 2010
  2. doi Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
    R Yerushalmi
    Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
    Ann Oncol 23:876-81. 2012
  3. ncbi Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
    R Yerushalmi
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Cancer Center, Vancouver, Canada
    Ann Oncol 23:338-45. 2012
  4. doi Patterns of relapse in breast cancer: changes over time
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, V5Z 4E6, Canada
    Breast Cancer Res Treat 120:753-9. 2010
  5. doi A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009
  6. ncbi Breast carcinoma--rare types: review of the literature
    R Yerushalmi
    British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 20:1763-70. 2009
  7. ncbi Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
    R Yerushalmi
    Institute of Oncology, Davidoff Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Ann Oncol 20:437-40. 2009
  8. doi Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, Canada V5Z 4E6
    Breast Cancer Res Treat 117:365-70. 2009
  9. doi Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study
    Alona Zer
    Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel alonaz clalit org il
    Chemotherapy 58:95-101. 2012
  10. ncbi Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
    David Loven
    Institute of Oncology, Ha Emek Medical Center, Afula 18101, Israel
    Acta Oncol 47:104-9. 2008

Detail Information

Publications25

  1. doi Ki67 in breast cancer: prognostic and predictive potential
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Lancet Oncol 11:174-83. 2010
    ....
  2. doi Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
    R Yerushalmi
    Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
    Ann Oncol 23:876-81. 2012
    ..We compared outcomes after breast-conserving therapy (BCT) and mastectomy in multicentric (MC)/multifocal (MF) versus unifocal breast cancer...
  3. ncbi Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
    R Yerushalmi
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Cancer Center, Vancouver, Canada
    Ann Oncol 23:338-45. 2012
    ..Little is known about the correlations between tumor markers (TMs), breast cancer subtypes, site(s) of metastasis and prognosis...
  4. doi Patterns of relapse in breast cancer: changes over time
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, V5Z 4E6, Canada
    Breast Cancer Res Treat 120:753-9. 2010
    ..Understanding patterns of relapse may help design new adjuvant strategies...
  5. doi A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009
    ....
  6. ncbi Breast carcinoma--rare types: review of the literature
    R Yerushalmi
    British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 20:1763-70. 2009
    ..This may also stand as a clinical framework for a future understanding of these rarer breast cancers when gene analysis work is reported...
  7. ncbi Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
    R Yerushalmi
    Institute of Oncology, Davidoff Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Ann Oncol 20:437-40. 2009
    ..Prompted by complaints of dyspnea in breast cancer patients receiving adjuvant dose-dense chemotherapy (DDC), we sought to evaluate the possible association of DDC with pulmonary dysfunction...
  8. doi Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC, Canada V5Z 4E6
    Breast Cancer Res Treat 117:365-70. 2009
    ..174 (95% CI 1,004, 1.372). Conclusions M/M breast cancer did not increase the risk of metachronous CBC, but was associated with inferior BCSS...
  9. doi Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study
    Alona Zer
    Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel alonaz clalit org il
    Chemotherapy 58:95-101. 2012
    ..Despite the growing number of clinical trials assessing preoperative systemic chemotherapy (PST) for locally advanced breast cancer, the optimal regimen has still to be defined...
  10. ncbi Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
    David Loven
    Institute of Oncology, Ha Emek Medical Center, Afula 18101, Israel
    Acta Oncol 47:104-9. 2008
    ..Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored...
  11. pmc Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis
    Irit Ben-Aharon
    Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tiqva, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 8:e70044. 2013
    ..The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC...
  12. pmc Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin
    Yulia Kundel
    Institue of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
    PLoS ONE 8:e68327. 2013
    ....
  13. pmc Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity
    Irit Ben-Aharon
    Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tiqva, Israel
    Oncologist 17:1386-93. 2012
    ..Studies in mice revealed that chemotherapy-induced gonadal toxicity may result from vascular damage. We prospectively evaluated ovarian blood flow and function in young breast cancer patients following chemotherapy...
  14. doi A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes
    Alan M Nichol
    British Columbia Cancer Agency Vancouver Centre, Vancouver, BC, Canada
    J Clin Oncol 29:4763-8. 2011
    ..The purpose of this study was to determine whether survival outcomes for patients with SBBC can be estimated from the characteristics of their individual cancers...
  15. doi Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
    Rinat Yerushalmi
    Division of Medical Oncology, BC Cancer Agency, Cancer Agency, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Breast Cancer Res Treat 132:131-42. 2012
    ..Results may have relevance to the development of therapeutics targeting IGF-1R...
  16. doi Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  17. doi Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study
    Daniel Hendler
    Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
    Am J Clin Oncol 34:619-24. 2011
    ....
  18. doi Chemotherapy for oestrogen-receptor-negative breast cancer
    Rinat Yerushalmi
    British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6
    Lancet 371:4-5. 2008
  19. ncbi Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil
    Rinat Yerushalmi
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Surg Oncol 93:529-33. 2006
    ..We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5-fluorouracil (5-FU) in the preoperative chemoradiation treatment of patients with rectal cancer...
  20. doi Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    Karen A Gelmon
    BC Cancer Agency, Vancouver, Canada
    Lancet Oncol 12:852-61. 2011
    ..We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer...
  21. ncbi Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy
    Claude Koren
    Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Am J Clin Oncol 25:625-6. 2002
    ..Clinicians should be aware of this potential side effect so that early premedication regimens can be instituted to prevent unnecessary toxicity...
  22. ncbi Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study
    David Margel
    Division of Urology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
    BMC Cancer 14:528. 2014
    ..However, prior studies did not systematically perform prostate biopsies and thus cannot determine the true prevalence of prostate cancer in this population...
  23. ncbi The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort
    Tal Grenader
    Institute of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel
    Oncology 87:1-6. 2014
    ..Conclusion: Our data suggest that the distribution of Oncotype DX RS in ER-positive MBC patients is similar to that of female breast cancer patients. © 2014 S. Karger AG, Basel. ..
  24. ncbi Treatment of neuroblastoma using the fused imaging guided radiotherapy (FIGURA) system
    Eyal Fenig
    Institute of Oncology, Radiation Therapy Unit, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel
    Clin Nucl Med 31:256-8. 2006
    ..The purpose of this study was to describe our department's experience with the fused imaging-guided radiotherapy (FIGURA) system for planning radiation treatment of high-risk neuroblastoma...
  25. ncbi Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathway
    Eyal Fenig
    Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel
    Oncol Rep 9:875-7. 2002
    ..Understanding these pathways may enable active intervention to alter the therapeutic ratio favorably in the treatment of breast cancer...